Our technology has advanced, our diagnostics have improved and our testing capability has advanced since the beginning of this pandemic, says Dr. Nicole Saphier, Fox News medical contributor. The Food and Drug Administration (FDA) warned about the possibility of false positives that can occur when using rapid antigen tests to detect coronavirus, particularly if the test is not used correctly. The regulatory agency said it has received reports of false-positive results occurring in nursing homes and other health care settings. The agency warned that reading the test results either before or after the specified time provided in the instructions can result in false-positive or false-negative results. It also referenced the antigen EUA conditions of authorization, which specifies that authorized laboratories are to follow the manufacturer's instructions for use regarding administering the test and reading the results.

The U.S. Congress should create a federal agency for artificial intelligence. In 1906, in response to shocking reports about the disgusting conditions in U.S. meat-packing facilities, Congress created the Food and Drug Administration (FDA) to ensure safe and sanitary food production. In 1934, in the wake of the worst stock market crash in U.S. history, Congress created the Securities and Exchange Commission (SEC) to regulate capital markets. In 1970, as the nation became increasingly alarmed about the deterioration of the natural environment, Congress created the Environmental Protection Agency (EPA) to ensure cleaner skies and waters. When an entire field begins to create a broad set of challenges for the public, demanding thoughtful regulation, a proven governmental approach is to create a federal agency focused specifically on engaging with and managing that field.

University of California San Diego School of Medicine and Moores Cancer Center say they have created a new artificial intelligence (AI) system called DrugCell that reportedly matches tumors to the best drug combinations, but does so in way that clearly makes sense. "That's because right now we can't match the right combination of drugs to the right patients in a smart way," said Trey Ideker, PhD, professor at University of California San Diego School of Medicine and Moores Cancer Center. "And especially for cancer, where we can't always predict which drugs will work best given the unique, complex inner workings of a person's tumor cells." Currently, Only four percent of all cancer therapeutic drugs under development earn final approval by the FDA. In a paper "Predicting Drug Response and Synergy Using a Deep Learning Model of Human Cancer Cells" published in Cancer Cell, Ideker, Brent Kuenzi, PhD, and Jisoo Park, PhD, postdoctoral researchers in his lab, published a paper on their work.

A new artificial intelligence (AI) system called DrugCell, developed by researchers at University of California San Diego School of Medicine and Moores Cancer Center can reportedly match tumors to the best drug combinations, in a way that has not bee possible previously. "That's because right now we can't match the right combination of drugs to the right patients in a smart way," said Trey Ideker, PhD, professor at University of California San Diego School of Medicine and Moores Cancer Center. "And especially for cancer, where we can't always predict which drugs will work best given the unique, complex inner workings of a person's tumor cells." Currently, Only four percent of all cancer therapeutic drugs under development earn final approval by the FDA. In a paper "Predicting Drug Response and Synergy Using a Deep Learning Model of Human Cancer Cells" published in Cancer Cell, Ideker, Brent Kuenzi, PhD, and Jisoo Park, PhD, postdoctoral researchers in his lab, published a paper on their work.

Asymptomatic spread of COVID-19 is a huge contributor to the pandemic, but of course if there are no symptoms, how can anyone tell they should isolate or get a test? MIT research has found that hidden in the sound of coughs is a pattern that subtly, but reliably, marks a person as likely to be in the early stages of infection. It could make for a much-needed early warning system for the virus. The sound of one's cough can be very revealing, as doctors have known for many years. AI models have been built to detect conditions like pneumonia, asthma and even neuromuscular diseases, all of which alter how a person coughs in different ways.

MIT researchers have identified a powerful new antibiotic compound using a machine-learning algorithm. A deep-learning model identifies a powerful new drug that can kill many species of antibiotic-resistant bacteria. Using a machine-learning algorithm, MIT researchers have identified a powerful new antibiotic compound. In laboratory tests, the drug killed many of the world's most problematic disease-causing bacteria, including some strains that are resistant to all known antibiotics. It also cleared infections in two different mouse models.

Federal regulators have cleared dozens of AI products used in health care, which might give the impression that the Food and Drug Administration has a firm handle on a technology that is already changing how patients are treated. But a meeting on AI regulation last week told a different story. The agency is still grappling with fundamental questions about algorithmic bias, data transparency, and how to ensure that patients benefit equally from AI's rapid progress in medicine. Unlock this article by subscribing to STAT and enjoy your first 30 days free! STAT is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

The environments in which we deploy machine learning (ML) algorithms rarely look exactly like the environments in which we collected our training data. Unfortunately, we lack methodology for evaluating how well an algorithm will generalize to new environments that differ in a structured way from the training data (i.e., the case of dataset shift (Quiñonero-Candela et al., 2009)). Such methodology is increasingly important as ML systems are being deployed across a number of industries, such as health care and personal finance, in which system performance translates directly to real-world outcomes. Further, as regulation and product reviews become more common across industries, system developers will be expected to produce evidence of the validity and safety of their systems. For example, the United States Food and Drug Administration (FDA) currently regulates ML systems for medical applications, requiring evidence for the validity of such systems before approval is granted (US Food and Drug Administration, 2019). Evaluation methods for assessing model validity have typically focused on how the model performs on data from the training distribution, known as internal validity. Powerful tools, such as cross-validation and the bootstrap, satisfy the assumption that the training and test data are drawn from the same distribution. However, these validation methods do not capture a model's ability to generalize to new environments, known as external validity (Campbell and Stanley, 1963). Currently, the main way to assess a model's external validity is to empirically evaluate performance on multiple, independently collected datasets (e.g.,

At a virtual meeting of the U.S. Food and Drug Administration's Center for Devices and Radiological Health and Patient Engagement Advisory Committee on Thursday, regulators offered updates and new discussion around medical devices and decision support powered by artificial intelligence. One of the topics on the agenda was how to strike a balance between safety and innovation with algorithms getting smarter and better trained by the day. In his discussion of AI and machine learning validation, Bakul Patel, director of the FDA's recently-launched Digital Health Center of Excellence, said he sees huge breakthroughs on the horizon. "This new technology is going to help us get to a different place and a better place," said Patel. You're seeing automated image diagnostics.

While AI and machine learning have the potential for transforming healthcare, the technology has inherent biases that could negatively impact patient care, senior FDA officials and Philips' head of global software standards said at the meeting. Bakul Patel, director of FDA's new Digital Health Center of Excellence, acknowledged significant challenges to AI/ML adoption including bias and the lack of large, high-quality and well-curated datasets. "There are some constraints because of just location or the amount of information available and the cleanliness of the data might drive inherent bias. We don't want to set up a system and we would not want to figure out after the product is out in the market that it is missing a certain type of population or demographic or other other aspects that we would have accidentally not realized," Patel said. Pat Baird, Philips' head of global software standards, warned without proper context there will be "improper use" of AI/ML-based devices that provide "incorrect conclusions" provided as part of clinical decision support.